Loading stock…

Indivior Pharmaceuticals, Inc. (INDV) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Indivior Pharmaceuticals, Inc.

INDVMarket cap $4.26BPrice $36.1

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and markets treatments for opioid use disorder, including Suboxone, a drug that helped define modern addiction medicine. Indivior fights a public health crisis that kills more Americans annually than car crashes and gun deaths combined.

In Bastion Portfolios?

52W Return+48%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+8%5

Rev CAGR (3y)+7%5

Rev CAGR (5y)+5%4

Earnings Forecast

EPS Growth Y+1+182%10

EPS Growth Y+2+8%6

EPS Growth Y+3+0%4

Quality

Margins

EBIT Margin43%10

Net Income Margin27%9

Free Cash Flow Margin-8%2

Debt

Net Debt/EBITDA0.57

Efficiency

ROEna–

ROA27%10

Earnings Stability44

GEAR+AVERAGE63

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)810

P/E Ratio (Forward 3y)79

P/BVna–

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd610

Yield

Free Cash Flow Yield-2.6%2

Dividend Yieldna–

Momentum

Short term

1 month return+5%9

3 month return-12%3

YTD return+1%5

Mid term

Price vs 52wHigh84%6

1 year return+50%9

Long term

3 year return+72%7

5 year return+142%8

Risk Shield

Price Risk

Beta0.76

Volatility36%5

Free Cash Flow

Free Cash Flow Margin-8%2

Free Cash Flow Yield-2.6%2

Quality

ROCE149%10

Earnings Stability44

Net Debt/EBITDA0.57

02Growth

Is it actually growing, and how fast?

INDVIndivior Pharmaceuticals

Revenue FY25$1.2B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+182%10

EPS growth, FY27E+8%6

EPS growth, FY28E+0%4

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 11%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return-12%3

YTD return+1%5

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+50%9

3-year return+72%7

5-year return+142%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +72% over three years and +142% over five, ahead of 70% of the market.

It's up 50% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%).

WATCH

Returns sit at the market level so far this year (+1%).

WEAKNESSES

The stock is underperforming over three months (-12%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Indivior Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

INDVIndivior Pharmaceuticals

Revenue FY25$1.2B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+182%10

EPS growth, FY27E+8%6

EPS growth, FY28E+0%4

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 11%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return-12%3

YTD return+1%5

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+50%9

3-year return+72%7

5-year return+142%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +72% over three years and +142% over five, ahead of 70% of the market.

It's up 50% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%).

WATCH

Returns sit at the market level so far this year (+1%).

WEAKNESSES

The stock is underperforming over three months (-12%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Indivior Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community